RIPE-KG · Version 1.1.0 · Resource
ripekg:retraction-notice/59331
https://w3id.org/ripe/ripe-kg/retraction-notice/59331
| Subject | Predicate | Object |
|---|---|---|
ripekg:evaluation/RIPEA3143964EFAC9FCC7 |
prov:used |
ripekg:retraction-notice/59331Efficacy and Risk Factors of Pyrrotinib in Second- and Third-Line Treatments for HER2-Positive Advanced Breast Cancer |
ripekg:retraction-notice/59331Efficacy and Risk Factors of Pyrrotinib in Second- and Third-Line Treatments for HER2-Positive Advanced Breast Cancer |
prism:doi |
10.1155/2023/9868302 |
ripekg:retraction-notice/59331Efficacy and Risk Factors of Pyrrotinib in Second- and Third-Line Treatments for HER2-Positive Advanced Breast Cancer |
prism:publicationDate |
2023-12-13 |
ripekg:retraction-notice/59331Efficacy and Risk Factors of Pyrrotinib in Second- and Third-Line Treatments for HER2-Positive Advanced Breast Cancer |
prism:publicationName |
Computational and Mathematical Methods in Medicine |
ripekg:retraction-notice/59331Efficacy and Risk Factors of Pyrrotinib in Second- and Third-Line Treatments for HER2-Positive Advanced Breast Cancer |
dcterms:publisher |
ripekg:publisher/RIPEP170EADD0429B0D42Hindawi |
ripekg:retraction-notice/59331Efficacy and Risk Factors of Pyrrotinib in Second- and Third-Line Treatments for HER2-Positive Advanced Breast Cancer |
dcterms:title |
Efficacy and Risk Factors of Pyrrotinib in Second- and Third-Line Treatments for HER2-Positive Advanced Breast Cancer |
ripekg:retraction-notice/59331Efficacy and Risk Factors of Pyrrotinib in Second- and Third-Line Treatments for HER2-Positive Advanced Breast Cancer |
http://purl.org/spar/cito/retracts |
ripekg:work/10.1155%2F2022%2F7864114 |
ripekg:retraction-notice/59331Efficacy and Risk Factors of Pyrrotinib in Second- and Third-Line Treatments for HER2-Positive Advanced Breast Cancer |
rdf:type |
http://purl.org/spar/fabio/RetractionNotice |
ripekg:retraction-notice/59331Efficacy and Risk Factors of Pyrrotinib in Second- and Third-Line Treatments for HER2-Positive Advanced Breast Cancer |
rdf:type |
rdfs:Resource |
ripekg:retraction-notice/59331Efficacy and Risk Factors of Pyrrotinib in Second- and Third-Line Treatments for HER2-Positive Advanced Breast Cancer |
rdf:type |
owl:Thing |
ripekg:retraction-notice/59331Efficacy and Risk Factors of Pyrrotinib in Second- and Third-Line Treatments for HER2-Positive Advanced Breast Cancer |
rdf:type |
ripe:IntegrityAssessmentEvidenceIntegrity assessment evidence |
ripekg:retraction-notice/59331Efficacy and Risk Factors of Pyrrotinib in Second- and Third-Line Treatments for HER2-Positive Advanced Breast Cancer |
rdf:type |
ripe:RetractionNoticeRetraction notice |
ripekg:retraction-notice/59331Efficacy and Risk Factors of Pyrrotinib in Second- and Third-Line Treatments for HER2-Positive Advanced Breast Cancer |
rdf:type |
tido:Evidence |
ripekg:retraction-notice/59331Efficacy and Risk Factors of Pyrrotinib in Second- and Third-Line Treatments for HER2-Positive Advanced Breast Cancer |
rdf:type |
tido:PieceOfInformation |
ripekg:retraction-notice/59331Efficacy and Risk Factors of Pyrrotinib in Second- and Third-Line Treatments for HER2-Positive Advanced Breast Cancer |
owl:sameAs |
https://semopenalex.org/work/W4389668835 |
ripekg:retraction-notice/59331Efficacy and Risk Factors of Pyrrotinib in Second- and Third-Line Treatments for HER2-Positive Advanced Breast Cancer |
prov:wasAttributedTo |
ripekg:source/retraction-watchRetraction Watch |
ripekg:retraction-notice/59331Efficacy and Risk Factors of Pyrrotinib in Second- and Third-Line Treatments for HER2-Positive Advanced Breast Cancer |
prov:wasAttributedTo |
ripekg:source/retraction-watchRetraction Watch Database |
ripekg:retraction-notice/59331Efficacy and Risk Factors of Pyrrotinib in Second- and Third-Line Treatments for HER2-Positive Advanced Breast Cancer |
prov:wasGeneratedBy |
ripekg:evidence-aggregation/RIPEA3143964EFAC9FCC7 |
ripekg:retraction-notice/59331Efficacy and Risk Factors of Pyrrotinib in Second- and Third-Line Treatments for HER2-Positive Advanced Breast Cancer |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA3143964EFAC9FCC7 |
ripekg:retraction-notice/59331Efficacy and Risk Factors of Pyrrotinib in Second- and Third-Line Treatments for HER2-Positive Advanced Breast Cancer |
ripe:concerns |
ripekg:author/RIPEAU3DFC7908A996378CYang Yang |
ripekg:retraction-notice/59331Efficacy and Risk Factors of Pyrrotinib in Second- and Third-Line Treatments for HER2-Positive Advanced Breast Cancer |
ripe:concerns |
ripekg:work/10.1155%2F2022%2F7864114 |
ripekg:retraction-notice/59331Efficacy and Risk Factors of Pyrrotinib in Second- and Third-Line Treatments for HER2-Positive Advanced Breast Cancer |
ripe:rationale |
Fake Peer Review;Investigation by Journal/Publisher;Investigation by Third Party;Paper Mill;Unreliable Results and/or Conclusions |
ripekg:retraction-notice/59331Efficacy and Risk Factors of Pyrrotinib in Second- and Third-Line Treatments for HER2-Positive Advanced Breast Cancer |
ripe:retractionWatchRecordId |
59331 |
ripekg:retraction-notice/59331Efficacy and Risk Factors of Pyrrotinib in Second- and Third-Line Treatments for HER2-Positive Advanced Breast Cancer |
tido:supports |
ripekg:integrity-assessment-hypothesis/RIPEA3143964EFAC9FCC7-human-1-3 |
ripekg:retraction-notice/59331Efficacy and Risk Factors of Pyrrotinib in Second- and Third-Line Treatments for HER2-Positive Advanced Breast Cancer |
tido:supports |
ripekg:integrity-assessment-hypothesis/RIPEA3143964EFAC9FCC7-inspectai-1-3 |